Publications and Digital Products

This Advisory is based on TIP 53, Addressing Viral Hepatitis in People with Substance Use Disorders. It offers guidance to providers and administrators in substance use disorder treatment programs on screening for, and treating clients with, hepatitis A, hepatitis B, and hepatitis C infections.

This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders (SUDs) and TIP 32, Treatment of Adolescents with SUDs. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

This Advisory is based on TIP 50, Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment. It provides strategies for identifying and addressing suicidal thoughts and behaviors among individuals with substance use disorders (SUDs).

This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for substance use disorder (SUD) treatment providers to effectively engage people with HIV in SUD treatment.

This updated TIP is designed to help providers and others better understand how to identify, manage, and prevent substance misuse in older adults. The TIP describes the unique ways in which the signs and symptoms of substance use disorder (SUD) manifest in older adults; drug and alcohol use disorder screening tools, assessments, and treatments specifically tailored for older clients' needs; the interaction between SUDs and cognitive impairment; and strategies to help providers improve their older clients' social functioning and overall wellness.

This guide supports health care providers, systems, and communities seeking to treat stimulant use disorders. It describes relevant research findings, examines best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This Advisory can help clinicians who work in a mental health facility implement a tobacco cessation program to reduce the use of tobacco-related products and tobacco-related diseases among clients with SMI.